Valeant eyeing merger but smaller buys more likely now -CEO

Tue May 28, 2013 8:46am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 28 (Reuters) - Valeant Pharmaceuticals International Inc continues to have discussions about a potential "merger of equals," but cannot predict the timing, Chief Executive Michael Pearson said on Tuesday.

Valeant, which has agreed to buy Bausch & Lomb for $8.7 billion, is not likely to make another major transaction in the near term, but is looking for smaller acquisitions, Pearson said on a conference call with analysts.